2023
Idiopathic myointimal hyperplasia of the mesenteric veins: A systematic review and individual patient data regression analysis
Rozner R, Gisriel S, Damianos J, Grimshaw A, Rizwan R, Nawaz A, Chan K, Wan D, Pantel H, Bhutta A, Fenster M, Brandt L, Barbieri A, Robert M, Feuerstadt P, Li D. Idiopathic myointimal hyperplasia of the mesenteric veins: A systematic review and individual patient data regression analysis. Journal Of Gastroenterology And Hepatology 2023, 38: 1040-1046. PMID: 37086041, DOI: 10.1111/jgh.16193.Peer-Reviewed Original ResearchConceptsIdiopathic myointimal hyperplasiaColonic ischemiaMesenteric veinRectal bleedingRectal involvementMyointimal hyperplasiaSystematic reviewYounger ageMultivariate logistic regression analysisCurative surgical resectionInferior mesenteric veinPre-surgical identificationLogistic regression analysisRegression analysisIschemic colitisAbdominal painMucosal ulcerationEndoscopic findingsSelect patientsSurgical resectionUncommon causeDiagnostic delaySurgical treatmentClinical featuresHospital records
2020
Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.
Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology Case Reports 2020, 3 PMID: 33778814, PMCID: PMC7993656.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyElective colectomyUlcerative colitisInhibitor therapyMetastatic melanomaImmune-related adverse eventsExcellent tumor responseImmune checkpoint inhibitorsSevere ulcerative colitisActive ulcerative colitisCheckpoint inhibitor immunotherapyCheckpoint inhibitor treatmentInflammatory bowel diseaseEffective treatment optionBenefits of treatmentImmune system activationTumor cell destructionCheckpoint inhibitorsAdvanced malignanciesAdverse eventsSelect patientsBowel diseaseAutoimmune diseasesTreatment optionsTumor response